Online inquiry

IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10915MR)

This product GTTS-WQ10915MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10915MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2966MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ9257MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ12214MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ14234MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ3747MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ2354MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ1758MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ3772MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-1834942
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW